The positive data from Phase 1/2a and open-label extension studies of zorevunersen in Dravet syndrome patients is a significant milestone for Stoke Therapeutics. The results not only show substantial seizure reduction but also cognitive improvements, which are critical for patient quality of life. The well-tolerated nature of the treatment further supports the company's plans for a Phase 3 study, indicating potential future success and market approval. This news is likely to positively impact STOK's stock price in the short term as it demonstrates progress in a critical area of unmet medical need.